Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Back

Showing results (1-10 of 99) with videos related to

Pageof 10
Sort By:
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|July 13, 2006
Drug-drug interactions that matterDavid J Back
Current Opinion in Infectious Diseases|April 20, 2002
Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter moleculesPatrick G Hoggard, David J Back
Fundamental & Clinical Pharmacology|May 25, 2005
The implications of P-glycoprotein in HIV: friend or foe?Andrew Owen, Becky Chandler, David J Back
Antiviral Therapy|August 26, 2009
Maraviroc: pharmacokinetics and drug interactionsSamantha Abel, David J Back, Manoli Vourvahis
Current Opinion in HIV and AIDS|April 18, 2009
Combining resistance and pharmacology for optimum patient careSaye H Khoo, Alan Winston, David J Back
AIDS (London, England)|January 10, 2015
Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approachMohammed Lamorde, Jonathan M Schapiro, David Burger, et al.
Pharmacogenetics and Genomics|September 27, 2006
Pharmacogenetics of HIV therapyAndrew Owen, Munir Pirmohamed, Saye H Khoo, et al.
The Journal of Antimicrobial Chemotherapy|June 28, 2020
The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeuticsMarco Siccardi, Jonathan Schapiro, Giovanni Di Perri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 20, 2011
IFN-γ 874A>T genotype is associated with higher CCR5 expression in peripheral blood mononuclear cells from HIV+ patientsNeill J Liptrott, Deirdre Egan, David J Back, et al.
Antiviral Therapy|May 4, 2005
Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitorsSimon P Jones, Omar Janneh, David J Back, et al.
Pageof 10

Showing results (1-10 of 99) with videos related to

Sort By:
Pageof 10
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|July 13, 2006
Drug-drug interactions that matterDavid J Back
Current Opinion in Infectious Diseases|April 20, 2002
Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter moleculesPatrick G Hoggard, David J Back
Fundamental & Clinical Pharmacology|May 25, 2005
The implications of P-glycoprotein in HIV: friend or foe?Andrew Owen, Becky Chandler, David J Back
Antiviral Therapy|August 26, 2009
Maraviroc: pharmacokinetics and drug interactionsSamantha Abel, David J Back, Manoli Vourvahis
Current Opinion in HIV and AIDS|April 18, 2009
Combining resistance and pharmacology for optimum patient careSaye H Khoo, Alan Winston, David J Back
AIDS (London, England)|January 10, 2015
Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approachMohammed Lamorde, Jonathan M Schapiro, David Burger, et al.
Pharmacogenetics and Genomics|September 27, 2006
Pharmacogenetics of HIV therapyAndrew Owen, Munir Pirmohamed, Saye H Khoo, et al.
The Journal of Antimicrobial Chemotherapy|June 28, 2020
The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeuticsMarco Siccardi, Jonathan Schapiro, Giovanni Di Perri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 20, 2011
IFN-γ 874A>T genotype is associated with higher CCR5 expression in peripheral blood mononuclear cells from HIV+ patientsNeill J Liptrott, Deirdre Egan, David J Back, et al.
Antiviral Therapy|May 4, 2005
Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitorsSimon P Jones, Omar Janneh, David J Back, et al.
Pageof 10